RCTJadad 0/5RandomizedDouble-BlindPlacebo-Controlled

NMN and NAD: What a 60-Day Trial Reveals About Blood Cells, Liver Markers, and "Optimal" Dosing

GeroScienceOctober 29, 2025Vol. 48 (3)

Summary

NMN (nicotinamide mononucleotide) has become one of the most hyped longevity supplements on the market, promising to boost NAD+ — a molecule your cells need for energy production and DNA repair, which naturally declines with age. But most of the buzz outpaces the data on what raising NAD actually does inside the body. This new post hoc analysis, published in GeroScience (Oct 2025), digs into that question using blood samples from a 60-day randomized, double-blind, placebo-controlled trial in 80 healthy, middle-aged adults (average age 49) in India. Participants took 300 mg, 600 mg, or 900 mg of NMN daily, or a placebo, and researchers tracked how their blood NAD levels related to standard laboratory panels — the same complete blood count, liver enzymes, and lipid markers you'd see on a routine checkup.

Two sets of findings emerged. First, at baseline (before any supplement), people who naturally had higher blood NAD tended to show a distinct laboratory signature: slightly higher lymphocytes and lower neutrophils (an immune cell balance shift), higher triglycerides and lower HDL ("good") cholesterol, and modestly higher liver enzymes (ALT and AST). None of these were dramatic — for example, each 1 nanomolar increase in NAD tracked with just a 0.02–0.36% shift in these markers — but the pattern raises the possibility that NAD status reflects broader metabolic and inflammatory conditions, not just an isolated "youth molecule."

Second, and more directly relevant to anyone taking NMN: as blood NAD rose over the 60 days of supplementation, so did hemoglobin, red blood cell (RBC) count, and mean corpuscular hemoglobin concentration (MCHC) — all markers of the blood's oxygen-carrying capacity. Uric acid also ticked up slightly. The authors frame this as a potentially favorable signal (better oxygen delivery to tissues), consistent with earlier reports from the same trial that higher NMN doses (especially 600 mg) improved six-minute walk test distance. Every change stayed within normal clinical reference ranges — nothing here suggests NMN pushed anyone into anemia, polycythemia, or gout territory.

It's worth being clear about what this study is and isn't. It's an exploratory, hypothesis-generating side-analysis (not the trial's original primary outcome), and it reports associations, not proof that NAD is causing these changes. Still, for a supplement category that's exploded with $30–$100/bottle products and sweeping anti-aging claims, this is a useful, sober look at what's actually measurable in the blood — both the possible upsides (blood oxygen capacity) and the reminder that "more NAD" isn't automatically "better" across every marker.

Sources: NutraIngredients coverage of the RBC findings, NutraIngredients interview with Prof. Andrea Maier on personalized NMN dosing, PubMed: original 300/600/900mg NMN dose-ranging trial, PubMed: this post hoc analysis

What This Means For You

If you're considering NMN, here's what this study actually supports — and doesn't. On dosing: this analysis pools data across 300, 600, and 900 mg/day arms rather than isolating one dose, but the parent trial (from the same research group) previously identified 600 mg/day as the sweet spot for raising NAD and improving six-minute walk distance, with diminishing returns at 900 mg. If you're going to try NMN, 600 mg/day is the most evidence-backed starting point among commercial doses, taken once daily, typically in the morning (most commercial NMN products are formulated as capsules or powders taken with or without food — check your specific product's label).

Who might see the most signal: the RBC/hemoglobin findings hint that people with borderline-low oxygen-carrying capacity (e.g., mild anemia tendencies, endurance athletes chasing marginal gains) are the ones to watch — though this wasn't tested as a defined subgroup here. Who should be cautious: the baseline association between higher NAD and higher triglycerides, lower HDL, and higher liver enzymes suggests anyone with existing dyslipidemia, fatty liver, or elevated uric acid/gout history should get baseline labs and monitor them if starting NMN, rather than assuming "more NAD = universally healthier." The uric acid increase is also worth flagging for anyone with gout risk.

When shopping: look for products that specify NMN purity (≥99%), third-party testing (NSF, USP, or Informed Sport), and a stated dose matching studied ranges (300–900 mg). Skip products relying on "proprietary blends" that hide actual NMN content. Given the modest effect sizes and remaining uncertainty, NMN is best considered a "maybe helpful, unlikely harmful at these doses" supplement rather than a must-have — pair any decision to try it with a basic blood panel before and after, and loop in a doctor if you have liver, lipid, or gout concerns.

Important Considerations

This is a post hoc, exploratory analysis — meaning researchers looked for patterns in blood work that weren't part of the trial's original pre-specified plan. That doesn't invalidate the findings, but it does mean they should be treated as hypothesis-generating rather than confirmed effects, and they haven't been independently replicated yet. All the reported relationships are correlations (a 1 nM change in NAD "associated with" a shift in a lab value) — the study cannot prove NMN caused these blood changes rather than some other factor tracking alongside NAD levels.

The sample is small (80 people) and narrow: healthy, middle-aged adults (avg. 49) in India with no major pre-existing conditions. Results may not generalize to older adults, people with chronic illness, different ethnic/genetic backgrounds, or those on medications — all groups notably underrepresented or excluded here. The Jadad quality score context flags that the paper's abstract doesn't fully describe the randomization or blinding methodology, so some methodological details couldn't be independently verified from the text available.

The effect sizes themselves are tiny in absolute terms (fractions of a percent per nanomolar of NAD), and every value — before and after — stayed within normal clinical reference ranges. This is not evidence of a dramatic health transformation; it's a fine-grained signal detectable only with statistical modeling across many participants. Be skeptical of any marketing that cites this study to claim NMN "boosts blood oxygen" or "reverses aging" — the researchers themselves describe the RBC findings as merely "potentially indicating" enhanced capacity, and call for larger, dedicated studies. Long-term safety data (beyond 60 days) and effects in people with existing liver, lipid, or kidney conditions remain unstudied. Talk to a doctor before starting NMN if you have relevant health conditions or take medications affecting liver enzymes, lipids, or uric acid.

Terms Explained

NAD (Nicotinamide Adenine Dinucleotide)A molecule found in every cell that's essential for turning food into energy and repairing DNA; blood/tissue levels naturally decline with age.

NMN (Nicotinamide Mononucleotide)A dietary supplement and direct precursor to NAD — the body converts NMN into NAD after ingestion, which is why it's marketed as a longevity/energy supplement.

Post hoc analysisA secondary look at trial data for patterns not specified before the study began — useful for generating new hypotheses but less rigorous than a pre-planned primary outcome.

Randomized, double-blind, placebo-controlled trialThe gold-standard study design where participants are randomly assigned to treatment or placebo, and neither participants nor researchers know who got which, minimizing bias.

Hemoglobin / RBC (red blood cell) countBlood markers reflecting how much oxygen your blood can carry to tissues; higher values (within normal range) generally suggest better oxygen delivery.

MCHC (Mean Corpuscular Hemoglobin Concentration)A measure of how concentrated hemoglobin is inside red blood cells, used alongside RBC count and hemoglobin to assess blood oxygen-carrying quality.

ALT / AST (liver enzymes)Alanine transaminase and aspartate transaminase — blood markers that rise when liver cells are stressed or damaged; commonly checked in routine metabolic panels.

HDL cholesterol"Good" cholesterol that helps clear excess cholesterol from the bloodstream; higher levels are generally considered protective for heart health.

Uric acidA waste product from purine breakdown; chronically elevated levels can contribute to gout and kidney stones.

Confidence interval (CI)A statistical range indicating the likely true value of an effect; a 95% CI that excludes zero is typically considered a statistically significant finding.

Technical Study Details

Study Design

Total Score

JADAD Quality Assessment

/ 5

評価詳細

Randomization

0 / 2

Is the study described as randomized?

Yes+1

Rationale: The abstract explicitly describes the underlying trial as "a randomized, double-blind, clinical trial," directly using the term "randomized" to characterize the study design.

Is the method of randomization described and appropriate?

No-1

Rationale: The abstract states the study was "randomized" but does not describe the specific method used to generate the randomization sequence (e.g., computer-generated random numbers, random number tables). Since no method is described at all in the available text, this criterion cannot be judged as appropriate, per Jadad scale scoring rules (undescribed method = "no").

Blinding

0 / 2

Is the study described as double-blind?

Yes+1

Rationale: The abstract explicitly states the study was a "randomized, double-blind, clinical trial," directly confirming that double-blinding was mentioned in the article.

Is the method of blinding described and appropriate?

No-1

Rationale: The abstract only states that the trial was "double-blind" and used a placebo comparator, but it does not describe the actual method of blinding (e.g., whether the placebo was identical in appearance, taste, packaging, or administration to the NMN capsules). Since no specific blinding methodology is described in the available text, there is insufficient information to confirm the blinding method was appropriate.

Dropouts/Withdrawals

0 / 1

Is there a description of dropouts and withdrawals?

No0

Rationale: The provided text is only the abstract of the article, which reports on a post hoc analysis of 80 participants but contains no statement regarding the number of or reasons for withdrawals or dropouts in each treatment group. No relevant text describing withdrawals/dropouts is present.

Outcome	Type	Effect	p-value
Lymphocyte percentage association with baseline NAD	Secondary	0.24 (0.05-0.44)	-Significant
Neutrophil percentage association with baseline NAD	Secondary	-0.36 (-0.57--0.14)	-Significant
Triglycerides association with baseline NAD	Secondary	0.02 (0.01-0.04)	-Significant
High-density lipoprotein (HDL) association with baseline NAD	Secondary	-0.01 (-0.01--0.00)	-Significant
Alanine transaminase (ALT) association with baseline NAD	Secondary	0.02 (0.00-0.04)	-Significant
Aspartate transaminase (AST) association with baseline NAD	Secondary	0.01 (0.00-0.02)	-Significant
Hemoglobin change association with NAD level increase	Secondary	0.03 (0.01-0.04)	-Significant
Red blood cell (RBC) count change association with NAD level increase	Secondary	0.03 (0.01-0.04)	-Significant
Mean corpuscular hemoglobin concentration (MCHC) change association with NAD level increase	Secondary	0.02 (0.01-0.03)	-Significant
Uric acid change association with NAD level increase	Secondary	0.02 (0.00-0.04)	-Significant

Conclusion

Higher baseline NAD levels are associated with inflammatory (lymphocyte/neutrophil), lipid (triglycerides/HDL), and liver (ALT/AST) profiles. NMN-induced increases in blood NAD are associated with increases in red blood cell parameters (hemoglobin, RBC, MCHC), potentially indicating enhanced oxygen-carrying capacity, as well as increased uric acid.

Limitations

Post hoc/exploratory analysis, not a prespecified primary or secondary outcome analysis
Associations reported are correlational and cannot establish causality